+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

European Metabolic Disorder Therapeutics Market 2020-2026

  • ID: 5240924
  • Report
  • November 2020
  • Region: Europe
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Merck KGaA
  • Novo Nordisk A/S
European metabolic disorder therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others) and Forecast, 2020-2026.

European metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.4% during the forecast period. Rising prevalence of metabolic disorders have been reported in the region, which is accelerating the growth of the market. According to the International Diabetes Federation (IDF), an estimated 59 million adults (20-79 years) were suffering from diabetes in the Europe Region. Europe has the largest number of adolescents and children (0-19 years) have type 1 diabetes, which is 296,500. Diabetes is a form of metabolic diseases that disrupt normal metabolism. Diabetic medications that are used for the treatment of the condition include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia) and pioglitazone (Actos)), and others. Rosiglitazone (Avandia) is intended for use as an adjunct to exercise and diet to improve glycemic control in adults suffering from type 2 diabetes mellitus. It is a highly potent and selective agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ)-responsive genes that participate in the regulation of fatty acid metabolism.

Based on country, the market is classified into UK, Germany, France, Spain, Italy, and Rest of Europe. UK is estimated to hold potential share in the market coupled with the significant prevalence of metabolic disorders in the country. As per the estimation by the Health Survey for England 2017, 28.7% of adults in England were obese and a further 35.6% are overweight. This leads to an increasing demand for metabolic drugs such as Orlistat (Xenical) and Phentermine. Orlistat (Xenical) works by reducing fat absorption by nearly 30%.

Some crucial players in the market include Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, and AstraZeneca plc. Partnerships and collaborations is one of the major strategies adopted by the market players to remain competitive in the market. For instance, in March 2020, AstraZeneca plc declared partnership with Silence Therapeutics for discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics to treat CVD, renal, respiratory, and metabolic disorders. This multi-target partnership will use the established small interfering RNA (siRNA) platform of Silence to detect and progress liver-based targets and develop new delivery methods to target other tissues including the heart, kidney, and lung.

Research Methodology

The market study of the European metabolic disorder therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. European Metabolic Disorder Therapeutics Market Research and Analysis by Therapy
2. European Metabolic Disorder Therapeutics Market Research and Analysis by Disease

The Report Covers:
  • Comprehensive research methodology of the European metabolic disorder therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European metabolic disorder therapeutics market.
  • Insights about market determinants which are stimulating the European metabolic disorder therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Merck KGaA
  • Novo Nordisk A/S
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Country

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. European Metabolic Disorder Therapeutics Market by Therapy
5.1.1. Drug Therapy
5.1.2. Gene Therapy
5.1.3. Cellular Transplantation
5.1.4. Enzyme Replacement Therapy
5.1.5. Others
5.2. European Metabolic Disorder Therapeutics Market by Disease
5.2.1. Obesity
5.2.2. Diabetes
5.2.3. Lysosomal Storage Disease
5.2.4. Hypercholesterolemia
5.2.5. Others

6. Regional Analysis
6.1. UK
6.2. Germany
6.3. France
6.4. Spain
6.5. Italy
6.6. Rest of European

7. Company Profiles
7.1. AbbVie Inc.
7.2. Actelion Pharmaceuticals Ltd.
7.3. AstraZeneca plc
7.4. Boehringer Ingelheim GmbH
7.5. Bristol-Myers Squibb Co.
7.6. Merck KGaA
7.7. Novo Nordisk A/S
7.8. Orchard Therapeutics plc
7.9. Sanofi S.A.
7.10. Shire Pharmaceuticals Group plc
7.11. Silence Therapeutics
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Merck KGaA
  • Novo Nordisk A/S
  • Orchard Therapeutics plc
  • Sanofi S.A.
  • Shire Pharmaceuticals Group plc
  • Silence Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll